Royce & Associates LP trimmed its stake in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 50.0% during the fourth quarter, Holdings Channel reports. The fund owned 10,000 shares of the medical equipment provider’s stock after selling 10,000 shares during the quarter. Royce & Associates LP’s holdings in ABIOMED were worth $1,874,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently bought and sold shares of ABMD. State of Tennessee Treasury Department acquired a new stake in shares of ABIOMED during the third quarter worth $5,058,000. Pratt Collard Advisory Partners LLC acquired a new stake in shares of ABIOMED during the fourth quarter worth $412,000. Hamilton Lane Advisors LLC raised its holdings in shares of ABIOMED by 50.8% during the fourth quarter. Hamilton Lane Advisors LLC now owns 23,241 shares of the medical equipment provider’s stock worth $4,356,000 after purchasing an additional 7,827 shares during the period. Janney Montgomery Scott LLC raised its holdings in shares of ABIOMED by 46.3% during the third quarter. Janney Montgomery Scott LLC now owns 2,903 shares of the medical equipment provider’s stock worth $489,000 after purchasing an additional 919 shares during the period. Finally, Cambridge Investment Research Advisors Inc. acquired a new stake in shares of ABIOMED during the third quarter worth $1,530,000. Hedge funds and other institutional investors own 87.37% of the company’s stock.
ABMD has been the topic of a number of research reports. Jefferies Group increased their target price on shares of ABIOMED to $250.00 and gave the stock a “buy” rating in a report on Friday, January 12th. BidaskClub raised shares of ABIOMED from a “hold” rating to a “buy” rating in a report on Thursday, January 11th. Piper Jaffray Companies reissued a “buy” rating on shares of ABIOMED in a report on Thursday, January 4th. Zacks Investment Research raised shares of ABIOMED from a “hold” rating to a “buy” rating and set a $213.00 target price on the stock in a report on Friday, December 29th. Finally, Leerink Swann increased their price objective on shares of ABIOMED from $200.00 to $265.00 and gave the stock an “outperform” rating in a report on Friday, January 19th. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $288.86.
Shares of ABIOMED, Inc. (NASDAQ:ABMD) opened at $281.54 on Wednesday. ABIOMED, Inc. has a twelve month low of $117.36 and a twelve month high of $285.48. The firm has a market cap of $12,365.47, a PE ratio of 142.19, a P/E/G ratio of 3.85 and a beta of 0.25.
ABIOMED (NASDAQ:ABMD) last released its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.70 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.50 by $0.20. ABIOMED had a net margin of 16.58% and a return on equity of 15.54%. The business had revenue of $154.00 million for the quarter, compared to analysts’ expectations of $154.00 million. During the same quarter last year, the company earned $0.34 EPS. The company’s revenue for the quarter was up 34.9% compared to the same quarter last year. research analysts predict that ABIOMED, Inc. will post 2.3 earnings per share for the current year.
In related news, VP Andrew J. Greenfield sold 20,000 shares of the stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $270.36, for a total value of $5,407,200.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 7.00% of the stock is owned by company insiders.
ABIOMED Company Profile
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).